STOCK TITAN
  1. Home
  2. Sec-filings
  3. MMED
  4. [Form 4] MiniMed Group, Inc. Insider Trading Activity

[Form 4] MiniMed Group, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

MiniMed Group, Inc. reported that EVP and Chief Financial Officer Chad Spooner received new equity awards. He was granted 27,778 performance-based restricted stock units, each representing one share of common stock, vesting on March 9, 2027, if MiniMed’s share price reaches at least $32.05 as of the Divestment Date. He also received options for 84,176 shares of common stock at an exercise price of $18.00 per share, vesting 33% on March 9, 2028, 33% on March 9, 2029, and 34% on March 9, 2030, with expiration on March 9, 2036.

Positive

  • None.

Negative

  • None.
Insider Spooner Chad
Role EVP, Chief Financial Officer
Type Security Shares Price Value
Grant/Award Performance-Based Restricted Stock Units 27,778 $0.00 $0.00
Grant/Award Employee Stock Option (Right to Buy) 84,176 $0.00 $0.00
Holdings After Transaction: Performance-Based Restricted Stock Units — 27,778 shares (Direct); Employee Stock Option (Right to Buy) — 84,176 shares (Direct)
Footnotes (3)
  1. F1. Each performance-based restricted stock unit represents a contingent right to receive one share of MMED common stock. The performance-based restricted stock units vest on March 9, 2027, subject to MMED common stock achieving a closing price per share of at least $32.05 as of the Divestment Date (as defined in the Separation Agreement, dated March 1, 2026, by and between Medtronic Group Holding, Inc. and Kangaroo US Holdco 2, Inc.).
  2. F2. The later of March 9, 2027 or the Divestment Date.
  3. F3. The option vests 33% on each of March 9, 2028 and March 9, 2029, and 34% on March 9, 2030.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Spooner Chad
(Last) (First) (Middle)
C/O 18000 DEVONSHIRE STREET
(Street)
NORTHRIDGE CA 91325
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
MiniMed Group, Inc. [ MMED ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP, Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Performance-Based Restricted Stock Units (1) 03/09/2026 A 27,778 (1) (2) Common Stock 27,778 $0 27,778 D
Employee Stock Option (Right to Buy) $18 03/09/2026 A 84,176 (3) 03/09/2036 Common Stock 84,176 $0 84,176 D
Explanation of Responses:
1. Each performance-based restricted stock unit represents a contingent right to receive one share of MMED common stock. The performance-based restricted stock units vest on March 9, 2027, subject to MMED common stock achieving a closing price per share of at least $32.05 as of the Divestment Date (as defined in the Separation Agreement, dated March 1, 2026, by and between Medtronic Group Holding, Inc. and Kangaroo US Holdco 2, Inc.).
2. The later of March 9, 2027 or the Divestment Date.
3. The option vests 33% on each of March 9, 2028 and March 9, 2029, and 34% on March 9, 2030.
Remarks:
/s/ Bryan F. Kelly, attorney-in-fact 03/11/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR